XALKORI CASE STUDY
Her cancer relapsed 58 months after the lobectomy, and she developed pulmonary and mediastinal lymph node metastases. Eight days later, the patient was unable to eat or drink. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer. Before beginning crizotinib, patients should be warned that visual disturbances may occur and that they might affect activities such as driving in the dark [ 34 ]. Adenocarcinoma cells were detected by cytological examination of the pleural effusion.
Support Center Support Center. Clinical course after administration of crizotinib. While they can continue to derive benefit from crizotinib beyond progression, patients will ultimately develop resistance and require a switch in therapy. Visual disturbances associated with crizotinib were generally transient and had little or no impact on activities of daily living [ 34 ]. Open in a separate window. Gastrointestinal endoscopy is usually required for the diagnosis of esophagitis, which supports the hypothesis that more cases of undocumented esophagitis may have occurred in patients undergoing crizotinib treatment compared with what was actually reported.
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
XALKORI case study
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: The ITT population in PROFILE comprised patients randomised to crizotinib and to chemotherapy who at the time of the primary analysis had been followed up for a median of Furthermore, at the time of writing, in post-marketing surveillance in Japan 8three cases of esophageal ulcers and six of esophagitis caused by crizotinib were reported; among these nine cases, three were severe.
No adjustments have been made to account for differences in the duration of treatment exposure between groups. Gastrointestinal endoscopy is usually required for the diagnosis of esophagitis, which supports the hypothesis that more cases of undocumented esophagitis may have occurred in patients undergoing crizotinib treatment compared with what was actually reported. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
The identification of novel targets for treatment has led to the development of new options that can improve outcomes in selected patients.
More on this topic Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. In the present case, ALK-positive cells were diagnosed using formalin-fixed, paraffin-embedded FFPE tissues that had been obtained five years previously.
Xalkori adverse drug reactions reported from the post-marketing surveillance in Japan. Overall, crizotinib has been shown to provide a valuable first- and second-line treatment option and is now the first-line standard of care for patients with advanced ALK -positive NSCLC.
Non-small-cell lung cancer NSCLC is the most commonly diagnosed type of cancer and is a leading cause of cancer-related mortality worldwide 1. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide.
Clinical experience with crizotinib in patients casse advanced ALK-rearranged non-small-cell lung cancer and brain metastases. A potential rationale for this observation is that ALK -positive tumours may express lower levels of thymidylate synthase than ALK -negative tumours [ 30 ]. Best tumour responses in patients with measurable disease are shown in Figure 1. In the present case, however, neutropenia first developed at 8 weeks and was not observed with rechallenge by dose-reduction of crizotinib.
Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. However, this resulted in a similar severity of neutropenia neutrophil count: A correction has been published: She underwent four cycles of cisplatin and vinorelbine as adjuvant therapy. Thereafter, ALK analysis was performed on the formalin-fixed, paraffin-embedded section from the previous surgical procedure; anti-ALK immunohistochemistry with the intercalated antibody-enhanced polymer method was positive, and EML4-ALK gene fusion was positive by fluorescence in situ hybridization.
Author information Article notes Copyright and License information Disclaimer. Median progression-free survival PFS was 9. Oxford University Press is a department of the University of Oxford.
Relapse was experienced following third-line chemotherapy with pemetrexed and anaplastic lymphoma kinase ALK -positive adenocarcinoma was diagnosed using a specimen from the resected ovarian tumor.
XALKORI case study | TIGCRU Insight
Adverse events that occurred with a frequency at least 5 percentage points greater in the crizotinib group compared with the chemotherapy group in both studies were vision disorder, diarrhoea, oedema, vomiting, constipation, elevated liver transaminases, upper respiratory tract infection, dysgeusia and dizziness Table 2.
Close mobile search navigation Article navigation. National Center for Biotechnology InformationU.
This article has been cited by other articles in PMC. N Engl J Med. Data are available from patients enrolled and treated up to Februaryof whom were evaluable for response.